Novartis’ Additional Indication Of Afinitor For Tuberous Sclerosis Treatment Approved
This article was originally published in PharmAsia News
Novartis Pharmaceuticals gained approval for anti-cancer Afinitor (everolimus) in the treatment of incurable tuberous sclerosis in Japan, the company announced Nov. 21.
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.